PMID- 31289598
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 10
IP  - 14
DP  - 2019
TI  - Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of 
      Cultured Circulating Tumor Cells from Bladder Cancer Patients.
PG  - 3259-3266
LID - 10.7150/jca.30079 [doi]
AB  - Objective: To explore whether cultured CTC from bladder-cancer patients originate 
      from bladder cancer and share chromosomal abnormalities, by means of a 
      fluorescence in situ hybridization (FISH) test. Methods: A total of 15 ml of 
      blood was collected from the patients with bladder cancer before treatment began. 
      Isolated CTCs were divided into 5 ml for CTC enumeration and 10 ml for CTC 
      culture. CTCs were counted by immunofluorescent staining with vimentin, 
      cytokeratin, CD45, and DAPI antibody. CTCs were cultured using isolated CTCs in 
      96-well plates of Mesenchymal Stem Cell Growth Medium for 16~18 days. The 
      resulting cultured CTCs from 20 men with bladder cancer were analyzed by 
      Urovysion FISH. Results: Common gains were on chromosome 3, 7, and 17 in 20 
      (74.1%), 14 (51.9%), and 20 (74.1%) of 27 patients, respectively. Polysomy was 
      detected on chromosomes 3 and 7 in 9 patients (33.3%). Polysomy involving two 
      chromosomes was observed in 16 (59.3%, chromosome 3 and 17) and 9 patients 
      (33.3%, chromosome 7 and 17) in the same cell. Among the patients with isolated 
      gain, 17 (63.0%) met the positive criteria for Urovysion FISH. Homozygous 
      deletion of 9p21, 5 (18.5%) involved more than 12 cells. Among the different 
      patient cohorts, positive results based on the Urovysion criteria were obtained 
      in cultured CTCs derived from 19 (70.4%) patients. Conclusion: Application of 
      FISH Urovysion to cultured CTCs from bladder cancer could be an effective first 
      step to confirm their origin and sharing of chromosomal abnormalities.
FAU - Kim, Tae-Jung
AU  - Kim TJ
AD  - Department of Hospital Pathology, College of Medicine, The Catholic University of 
      Korea, Seoul, Republic of Korea.
FAU - Moon, Hyong Woo
AU  - Moon HW
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Kang, Sungmin
AU  - Kang S
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Yang, Jonghyup
AU  - Yang J
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Hong, Sung-Hoo
AU  - Hong SH
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
AD  - The Cancer Research Institute, College of Medicine, The Catholic University of 
      Korea, Seoul, Republic of Korea.
FAU - Lee, Ji Youl
AU  - Lee JY
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
AD  - The Cancer Research Institute, College of Medicine, The Catholic University of 
      Korea, Seoul, Republic of Korea.
FAU - Ha, U-Syn
AU  - Ha US
AD  - Department of Urology, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
AD  - The Cancer Research Institute, College of Medicine, The Catholic University of 
      Korea, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20190602
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC6603370
OTO - NOTNLM
OT  - Circulating tumor cells
OT  - FISH Technique
OT  - bladder cancer
OT  - chromosomal abnormality
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2019/07/11 06:00
MHDA- 2019/07/11 06:01
PMCR- 2019/01/01
CRDT- 2019/07/11 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/04/28 00:00 [accepted]
PHST- 2019/07/11 06:00 [entrez]
PHST- 2019/07/11 06:00 [pubmed]
PHST- 2019/07/11 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - jcav10p3259 [pii]
AID - 10.7150/jca.30079 [doi]
PST - epublish
SO  - J Cancer. 2019 Jun 2;10(14):3259-3266. doi: 10.7150/jca.30079. eCollection 2019.